About Genomics
Genomics is a company based in Oxford (United Kingdom) founded in 2014 by Gil McVean and Peter Donnelly. It operates as a AI-as-a-Service, Professional Services, and HealthTech. Genomics has raised $115.54 million across 10 funding rounds from investors including Vertex Pharmaceuticals, HHS and University of Oxford. Genomics offers products and services including Health Insights, Drug Discovery Platform, and Precision Health Tools.
- Headquarter Oxford, United Kingdom
- Founders Gil McVean, Peter Donnelly
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genomics Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$115.54 M (USD)
in 10 rounds
-
Latest Funding Round
$44.51 M (USD), Series C
Jan 08, 2024
-
Investors
Vertex Pharmaceuticals
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genomics
Genomics offers a comprehensive portfolio of products and services, including Health Insights, Drug Discovery Platform, and Precision Health Tools.
Personalized health insights are provided through genomic analysis.
Drug discovery is accelerated using population-scale genetic data.
Precision health delivery is enabled through genetic stratification.
Funding Insights of Genomics
Genomics has successfully raised a total of $115.54M across 10 strategic funding rounds. The most recent funding activity was a Series C round of $44.51 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genomics
Genomics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Vertex Pharmaceuticals, HHS and University of Oxford.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital fund
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked |
Investor details for Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genomics
Investment portfolio details for Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genomics
Detailed financials for Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genomics Comparisons
Peer comparison for Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genomics
Detailed competitors of Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genomics
Complete news archive for Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genomics
Genomics was founded in 2014.
Genomics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Peter Donnelly is the current CEO of Genomics. They have also founded this company.
Genomics is a funded company, having raised a total of $115.54M across 10 funding rounds to date.
Genomics is engaged in harnessing genetic data to improve population health and accelerate drug discovery. Solutions are provided for healthcare providers, employers, life sciences, and partners through predictive genomics and personalized health insights. The company operates in the biotechnology sector, focusing on disease risk prediction and precision health delivery. Collaborations are maintained with global pharmaceutical companies and research institutions to develop innovative treatments and screening methods.
Genomics offers Health Insights, Drug Discovery Platform, and Precision Health Tools.
Genomics has 14 investors. Key investors include Vertex Pharmaceuticals, HHS, University of Oxford, IP Group, and Invesco Mutual Fund.